Study at a glance
How does chronic kidney disease change vitamin D processing?
This page summarises evidence about how chronic kidney disease changes vitamin D processing. The kidneys normally convert 25-hydroxyvitamin D, an earlier form, into calcitriol, the active hormone. They also recover vitamin D compounds from filtered blood and help control their breakdown. Kidney disease can disturb all these steps, not just activation.
Why can kidney disease make vitamin D activation less effective?
There may be less functioning kidney tissue, while hormone signals also change how the remaining tissue works. A hormone called fibroblast growth factor 23 (FGF23) can reduce activation. Parathyroid hormone often rises as the body tries to maintain calcium balance. Calcium and phosphate blood levels may remain fairly controlled for a time even when the underlying hormone system is disturbed.
Do losses in urine or faster vitamin D breakdown explain everything?
No. In one human study, reducing loss of vitamin D-binding protein in urine did not produce corresponding changes in blood vitamin D. Evidence also suggests that overall vitamin D processing can slow in kidney disease. Activation and breakdown can both become abnormal. A single routine vitamin D blood result cannot show how well all these processes are working.
What did vitamin D treatment studies in kidney disease show?
A review of trials found inconsistent effects of ordinary vitamin D supplements on parathyroid hormone. Other preparations, including active vitamin D, lowered it more consistently. Some active preparations also increased FGF23. These blood changes do not prove that normal kidney vitamin D regulation was fully restored. Evidence for major improvements in patients’ health remains less certain than evidence for changes in these blood markers.
Read the full article below ↓Chronic kidney disease can disrupt vitamin D metabolism through more than loss of the kidney’s ability to produce active hormone. Renal substrate recovery, CYP27B1 activation, CYP24A1-mediated metabolism and endocrine feedback involving PTH and FGF23 can all change as kidney function deteriorates. This helps explain why Vitamin D and Kidneys cannot be understood simply as a conversion of 25-hydroxyvitamin D [25(OH)D] into calcitriol. For the detailed evidence review, see Chronic Kidney Disease and Altered Vitamin D Metabolism: Full Evidence Review.
What happens to vitamin D metabolism when kidney function declines?
The kidney is the principal regulated source of circulating 1,25-dihydroxyvitamin D [1,25(OH)₂D, or calcitriol]. CYP27B1 in renal proximal tubular cells converts 25(OH)D into calcitriol, while CYP24A1 participates in further metabolism of both precursor and active vitamin D metabolites.
These pathways normally operate in balance. PTH tends to stimulate renal CYP27B1, whereas FGF23 and calcitriol suppress activation and can favour the catabolic side of the pathway. The underlying enzyme relationship is explained in Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1).
Reduced kidney mass is only part of the explanation
Loss of functioning nephrons reduces the tissue available for renal calcitriol production, but CKD also changes the regulatory environment of the remaining nephrons. FGF23 commonly rises as mineral handling becomes more difficult and can suppress renal CYP27B1. PTH often rises in the opposite direction as the body attempts to defend calcium balance.
The result is therefore not simply less enzyme because there is less kidney. The remaining renal tissue is operating within an altered endocrine system.
The kidney also has to recover vitamin D substrate
Much circulating 25(OH)D is carried by vitamin D-binding protein. Filtered DBP-bound 25(OH)D can be recovered by proximal tubular cells through megalin and cubilin, making substrate available for intracellular metabolism.
Proteinuric kidney disease can increase urinary loss of DBP. However, a human CKD study found that reducing urinary DBP loss did not produce corresponding changes in plasma DBP, 25(OH)D3 or 1,25(OH)₂D3. Urinary DBP loss therefore cannot by itself explain the complete vitamin D disturbance of CKD.
Vitamin D degradation does not move in one predictable direction
CYP24A1 is a major pathway for vitamin D metabolism and clearance, but CKD should not be described simply as a state of excessive vitamin D degradation. Evidence reviewed in CKD suggests that overall vitamin D turnover and formation of 24,25-dihydroxyvitamin D can also be reduced.
This means activation and degradation can both be abnormal. The broader role of turnover is developed in Vitamin D Clearance and Degradation.
Mineral regulation changes alongside vitamin D metabolism
Lower calcitriol availability can reduce part of the normal support for intestinal calcium absorption and weaken suppression of PTH. Secondary hyperparathyroidism can therefore emerge as CKD progresses.
FGF23 adds another feedback pathway. It promotes phosphate excretion by surviving nephrons while suppressing renal calcitriol production. Serum calcium and phosphate can consequently remain relatively controlled for a time even though the underlying endocrine system is increasingly disturbed.
The calcium component of this physiology is developed in Vitamin D and Calcium Physiology.
Why one vitamin D result cannot describe renal vitamin D function
25(OH)D and calcitriol are different parts of the pathway. A measurable 25(OH)D concentration does not prove that renal conversion to calcitriol is normal, while a change in calcitriol does not explain every aspect of vitamin D status.
Kidney disease can also alter substrate uptake, hormone feedback and metabolite turnover without those processes being visible in a single routine vitamin D result. This illustrates the wider principles in Vitamin D Homeostasis Mechanisms.
What intervention studies show
Clinical trials have tested nutritional vitamin D, calcifediol, calcitriol and vitamin D receptor activators in CKD. A systematic review found inconsistent PTH effects from nutritional vitamin D, while calcifediol and active vitamin D compounds more consistently reduced PTH in the included trials.
That biochemical effect should not be interpreted as proof that all aspects of CKD vitamin D physiology have been restored. Active analogues increased FGF23 in several studies, and evidence for major patient-level outcomes remains much less certain than evidence for changes in biochemical markers.
What the evidence means
The strongest conclusion is that CKD disrupts an integrated renal vitamin D system. Reduced functional kidney tissue matters, but so do substrate retrieval, CYP27B1 and CYP24A1 regulation, FGF23, PTH, calcium and phosphate physiology.
Kidney dysfunction therefore changes the meaning of vitamin D metabolism at several levels simultaneously. It is more accurate to think of CKD as disturbed vitamin D regulation than simply as failure to activate vitamin D.
Scientific sources
Cortney Bosworth and Ian H de Boer. Impaired Vitamin D Metabolism in CKD. Seminars in Nephrology. 2013;33(2):158-168. PMID 23465502. PMCID PMC3592201. DOI 10.1016/j.semnephrol.2012.12.016.
Adriana S Dusso. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney International Supplements. 2011;1(4):136-141. PMID 25018912. PMCID PMC4089671. DOI 10.1038/kisup.2011.30.
Christina Christodoulou, Maria Tsioufis, and colleagues. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcified Tissue International. 2021;109:157-178.
Carolina R C Doorenbos, Milton M de Cuba, Liffert Vogt, Ido P Kema, Jacob van den Born, Reinold O B Gans, Gerjan Navis and Martin H de Borst. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. Journal of Steroid Biochemistry and Molecular Biology. 2012;128(1-2):56-61. PMID 21958677. DOI 10.1016/j.jsbmb.2011.09.002.
Related reading
Altered metabolism of mothers of young children with Autism Spectrum Disorder: a case control study
Mothers of children with ASD have many significantly different metabolite levels compared to mothers of typically developing children at 2 to 5 years after birth.
Original paper ↗Read more →Economic burden of secondary hyperparathyroidism in Germany: a matched comparison
We aimed at assessing characteristics, healthcare resource utilization, and costs of incident SHPT patients in CKD stage 3 (CKD3) and 4 (CKD4), using administrative claims data.
Original paper ↗Read more →Effects of Exergames and Protein Supplementation on Body Composition and Musculoskeletal Function of Prefrail Community-Dwelling Older Women: A Randomized, Controlled Clinical Trial
This study aimed to investigate the effects of exergames and protein supplementation on the body composition and musculoskeletal function of pre-frail older women.
Original paper ↗Read more →Fibroblast growth factor 21 (FGF21) is a sensitive marker of osteoporosis in haemodialysis patients: a cross-sectional observational study
In this study, we investigated whether FGF21 could serve as a biomarker to predict osteoporosis in a haemodialysis cohort.
Original paper ↗Read more →Fibroblast growth factor 23, mineral metabolism and mortality among elderly men (Swedish MrOs)
The primary aim of this study is to examine the association between FGF23 and mortality, in relation to renal function in the community.
Original paper ↗Read more →Fluconazole in hypercalciuric patients with increased 1,25(OH)2D levels: the prospective, randomized, placebo-controlled, double-blind FLUCOLITH trial
Thus, the FLUCOLITH study is a unique opportunity to develop a new indication of a well-known and not expensive drug in orphan renal diseases, the ultimate objective being the secondary prevention of CKD worsening in these patients.
Original paper ↗Read more →Healthcare use and costs before and after parathyroidectomy in patients on dialysis
Prescription use, physician encounters, and surgical complications were compared during the six months immediately before and after PTX.
Original paper ↗Read more →Knowledge and Practice of Pediatricians Regarding Hypovitaminosis D: A Survey across 33 European Countries
This study aimed to evaluate the knowledge and practice of European pediatricians concerning vitamin D (VD) and hypovitaminosis D and their adherence to relevant guidelines.
Original paper ↗Read more →Mendelian randomization analysis reveals fresh fruit intake as a protective factor for urolithiasis
Previous studies have proposed that food intakes are associated with the risk of urolithiasis.
Original paper ↗Read more →NGF-β and BDNF levels are altered in male patients with chronic schizophrenia: effects on clinical symptoms
This study investigated NGF-β and BDNF levels in chronic schizophrenia and their association with clinical symptoms, cognitive function, and 1,25(OH)₂D levels.
Original paper ↗Read more →Phenotypes and the Importance of Genetic Analysis in Adult Patients with Nephrolithiasis and/or Nephrocalcinosis: A Single-Center Experience
We reviewed the phenotype of the patients and compared the cases with positive and negative molecular diagnosis.
Original paper ↗Read more →Quantitative CT screening improved lumbar BMD evaluation in older patients compared to dual-energy X-ray absorptiometry
The osteoporosis detection rates between QCT and DXA were compared.
Original paper ↗Read more →Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion
Vitamin D is recognized to play an essential role in health and disease.
Original paper ↗Read more →Real-world assessment: effectiveness and safety of extended-release calcifediol and other vitamin D therapies for secondary hyperparathyroidism in CKD patients
This study aimed to assess real-world experience of ERC and other vitamin D therapies in reducing PTH and increasing 25D.
Original paper ↗Read more →Reconsidering the Widespread Use of Active Vitamin D Analogues for Osteoporosis in Japan: A Call for Evidence-Based Prescription Practices
In Japan, active vitamin D has been widely prescribed for osteoporosis due to its regulatory approval, in contrast to international practice where it is not considered standard therapy.
Original paper ↗Read more →Serum 25-Hydroxyvitamin D and Cancer Risk: A Systematic Review of Mendelian Randomization Studies
Epidemiological studies suggest that higher serum 25-hydroxyvitamin D is associated with lower risk for several cancers, including breast, prostate, colorectal, and lung cancers.
Original paper ↗Read more →Serum Periostin as a Complementary Biomarker of Frailty in Type 2 Diabetes: A Pilot Study Using the FRAIL Scale
Identifying objective biochemical markers to complement clinical screening tools, such as the FRAIL scale, is an increasingly important unmet need.
Original paper ↗Read more →Vitamin D: Harmless Nutritional Supplement or Serious Medication?
Excessive vitamin D supplementation may result in significant clinical complications.
Original paper ↗Read more →Vitamin D status in ANCA-associated vasculitis
Vitamin D might participate in the pathogenesis of several immune-mediated diseases, but few related data are available for ANCA-associated vasculitis (AAV).
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Chronic Kidney Disease and Altered Vitamin D Metabolism: Full Evidence Review
How chronic kidney disease alters vitamin D activation, substrate handling, degradation, PTH, FGF23 and mineral regulation, with important physiological limits.
Read more →Original sources
Impaired Vitamin D Metabolism in CKD
Published in Seminars in Nephrology (2013).
Publication details
Cortney Bosworth and Ian H de Boer. Impaired Vitamin D Metabolism in CKD. Seminars in Nephrology. 2013;33(2):158-168. PMID 23465502. PMCID PMC3592201. DOI 10.1016/j.semnephrol.2012.12.016.
Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation
Published in Kidney International Supplements (2011).
Publication details
Adriana S Dusso. Kidney disease and vitamin D levels: 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and VDR activation. Kidney International Supplements. 2011;1(4):136-141. PMID 25018912. PMCID PMC4089671. DOI 10.1038/kisup.2011.30.
Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines
Published in Calcified Tissue International (2021).
Publication details
Christina Christodoulou, Maria Tsioufis, and colleagues. Vitamin D Supplementation for Patients with Chronic Kidney Disease: A Systematic Review and Meta-analyses of Trials Investigating the Response to Supplementation and an Overview of Guidelines. Calcified Tissue International. 2021;109:157-178.
Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease
Published in Journal of Steroid Biochemistry and Molecular Biology (2012).
Publication details
Carolina R C Doorenbos, Milton M de Cuba, Liffert Vogt, Ido P Kema, Jacob van den Born, Reinold O B Gans, Gerjan Navis and Martin H de Borst. Antiproteinuric treatment reduces urinary loss of vitamin D-binding protein but does not affect vitamin D status in patients with chronic kidney disease. Journal of Steroid Biochemistry and Molecular Biology. 2012;128(1-2):56-61. PMID 21958677. DOI 10.1016/j.jsbmb.2011.09.002.